Neuronal plasticity in neurodegenerative diseases. PI: Jordi Alberch Vié

Presentation

Dr. Alberch's group is interested in identifying new therapeutic targets to develop new treatments for Huntington's disease.

Mutated huntingtina activates a serie of intracellular mechanisms that produces selective degeneration of the striated nucleus projection neurons, initially the indirect pathway and later the direct route. This neuronal degeneration causes alterations in the basal ganglia circuits responsible for the symptomatology of the disease: motor disorder and cognitive disorders. Our research group has described in recent years different mechanisms involved in induced degeneration by mutant huntingtina, such as the characterization of neurotrophic factors in this process, especially the BDNF. Currently, the main objective of the group's research is the study of the molecular and cellular mechanisms activated by mutant huntingtina that alter the neuronal plasticity involved in the maintenance of the basal ganglia circuits affected by Huntington's disease.

Jordi Alberch Vié
Full professor
alberch@ub.edu

Mercè Masana Nadal
Assistant professor
mmasana@ub.edu

Sara Fernández García
Predoctoral Fellowship
sarafernandez@ub.edu

Ened Rodríguez Urgelles
Predoctoral researcher
enedrodriguez@ub.edu

Alfonso Gerardo García Diaz-Barriga
Predoctoral researcher
gerardogarcia@ub.edu

Esther Garcia Garcia
Predoctoral researcher
esthergarcia.192@gmail.com
 
Sara Conde Berriozabal
Predoctoral researcher
saracb.2906@gmail.com

  • BDNF/TrkB/p75 system implication in mechanisms of neuronal plasticity in Huntington's disease.

  • Control of the excitatory/inhibitor balance of cortical and striatal neuronal networks and their involvement in neurodegenerative processes.

  • Optogenetic study to assess the affectation on direct and indirect way in basal ganglia in altered motor coordination in Huntington's disease.

  • Identification of new drugs that recover functional connectivity (glutamate-dopamine-acetylcholine-gaba) from neuronal circuits to basal ganglia.

  • Institut de Neurociències de la Universitat de Barcelona (UBNEURO)

Project reference: MDM-2017-0729
PI: Jordi Alberch Vié
Affiliation entity: Universitat de Barcelona
Funding entity: Ministerio de Economia, Industria y Competitividad
Period: 01/07/2018 - 30/06/2022

  • Modulación de la Dinámica de las Redes Neuronales como Estrategia Terpeutica para Recuperar la Disfunción de los Ganglios Basales enlas Enfermedades del Movimiento

Project reference: SAF2017-88076-R
PI: Jordi Alberch Vié
Affiliation entity: Universitat de Barcelona
Funding entity: Ministerio de Economía y Competitividad
Period: 1/1/2018 - 31/12/2020
Amount: 326.700 €

  • Modulación de la plasticidad sináptica como estrategia terapéutica en la enfermedad de Huntington

Project reference: SAF2014-57160-R
PI: Jordi Alberch Vié / Cristina Malagelada Grau
Affiliation entity: Universitat de Barcelona
Funding entity: Ministerio de Economía y Competitividad
Period: 1/1/2015 - 31/12/2017
Amount: 270.000 €

  • Custom architecturally defined 3D stem cell derived functional human neural networks for transformative progress in neuroscience and medicine (MESO_BRAIN)

Project reference: 713140
PI: Jordi Soriano Fradera
Affiliation entity: Universitat de Barcelona
Funding entity: HORIZON 2020. PILLAR 1-EXCELLENT SCIENCE. FET. Future and Emerging Technologies.
Period: 1/1/2016 - 31/12/2019
Amount:  466.236 €

  • European Training Network for Cell-Based Regenerative Medicine (Training4CRM)

Project reference: 722779
PI: Jordi Alberch Vié / Josep M Canals
Affiliation entity: Universidad de Barcelona
Funding entity: HORIZON 2020. PILLAR 1-EXCELLENT SCIENCE. MCA. Marie Sklodowska-Curie Actions.
Period: 1/1/2016 - 31/12/2020
Amount: 247.872 €

  • Enfermedades neurodegenerativas: enfermedad de Huntington

Project reference: CIBER en enfermedades neurodegenerativas (CIBERNED)
PI: Jordi Alberch Vié
Affiliation entity: Universitat de Barcelona
Funding entity: Instituto de Salud Carlos III
Period: 2006 - 2019
Amount: 672.683 €

  • Fisiopatología y Tratamiento de las enfermedades neurodegenerativas

Project reference: 2014 SGR 968
PI: Jordi Alberch Vié
Affiliation entity: Universitat de Barcelona
Funding entity: Generalitat de Catalunya
Period: 2014 - 2016
Amount: 30.000 €

  • Red temática de terapia celular

Project reference: RD06/0010/0006
PI: Josep Maria Canals Coll
Affiliation entity: Instituto de Investigaciones Biomédicas August i Pi Sunyer (IDIBAPS)
Funding entity: Instituto de Salud Carlos III
Period: 2007-2017
Amount: 408.000 €

  • Modulation of synaptic plasticity deficits as therapeutic strategy in Huntington’s disease

PI: Jordi Alberch Vié / Isabel Pérez Otaño
Affiliation entity: Universitat de Barcelona
Funding entity: Fundació La Marató de TV3
Period: 2015 - 2017
Amount: 299.375 €

 

- Contracts, technological or transfer merits:

  • Identification of chorein function in neurodegeneration of the basal ganglia for developing new therapeutical approaches in Chorea-Acanthocytosis

PI: Jordi Alberch Vié
Funding entity: Fundación ChAc
Reference: 309965
Period: 2018 - 2020
Amount: 25.677 euros

  • Desarrollo experimental del tratamiento con AAT-1 como terapia antiinflamatoria en la isquemia neonatal (el Estudio A) y Ensayo de la AAT-1 en la lesión aguda de la médula espinal

PI: Jordi Alberch Vié
Funding entity: Instituto Grifols, S.A
Reference: 307272                                                               
Period: 2013 - 2018
Amount: 52.973 euros

For more information for PI publications click in the link:
ORCID: https://orcid.org/0000-0002-8684-2721
ResearcherID: http://www.researcherid.com/rid/K-5702-2014
Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=7003644890

Blázquez G, Castañé A, Saavedra A, Masana M, Alberch J, Pérez-Navarro E. Social Memory and Social Patterns Alterations in the Absence of STriatal-Enriched Protein Tyrosine Phosphatase. Front Behav Neurosci. 2019 Jan 25;12:317. doi: 10.3389/ fnbeh.2018.00317.  eCollection 2018. PMID: 30760987

de Pins B, Cifuentes-Díaz C, Farah AT, López-Molina L, Montalban E, Sancho-Balsells A, López A, Ginés S, Delgado-García JM, Alberch J, Gruart A, Girault JA, Giralt A. Conditional BDNF Delivery from Astrocytes Rescues Memory Deficits, Spine Density, and Synaptic Properties in the 5xFAD Mouse Model of Alzheimer Disease. J Neurosci. 2019 Mar 27; 39(13): 2441-2458. doi: 10.1523/ JNEUROSCI. 2121-18.2019. Epub 2019 Jan 30. PMID: 30700530

Montalban E, Al-Massadi O, Sancho-Balsells A, Brito V, de Pins B, Alberch J, Ginés S, Girault JA, Giralt A. Pyk2 in the amygdala modulates chronic stress sequelae via PSD-95-related micro-structural changes. Transl Psychiatry. 2019 Jan 15; 9(1):3. doi: 10.1038/ s41398-018-0352-y. PMID: 30664624

Siegert AM, García Díaz-Barriga G, Esteve-Codina A, Navas-Madroñal M, Gorbenko Del Blanco D, Alberch J, Heath S, Galán M, Egea G. A FBN1 3'UTR mutation variant is associated with endoplasmic reticulum stress in aortic aneurysm in Marfan syndrome. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):107-114. doi: 10.1016/ j.bbadis.2018.10.029. Epub 2018 Oct 30. PMID: 30385411

García-Forn M, Martínez-Torres S, García-Díaz Barriga G, Alberch J, Milà M, Azkona G, Pérez-Navarro E. Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease. Neurobiol Dis. 2018 Dec;120:88-97. doi: 10.1016/j.nbd.2018.08.024. Epub 2018 Aug 31. PMID: 30176350

Saavedra A, Ballesteros JJ, Tyebji S, Martínez-Torres S, Blázquez G, López-Hidalgo R, Azkona G, Alberch J, Martín ED, Pérez-Navarro E. Proteolytic Degradation of Hippocampal STEP61 in LTP and Learning. Mol Neurobiol. 2019 Feb;56(2):1475-1487. doi: 10.1007/s12035-018-1170-1. Epub 2018 Jun 12. PMID: 29948948

Cabezas-Llobet N, Camprubí S, García B, Alberch J, Xifró X. Human alpha 1-antitrypsin protects neurons and glial cells against oxygen and glucose deprivation through inhibition of interleukins expression. Biochim Biophys Acta Gen Subj. 2018 Sep;1862(9):1852-1861. doi: 10.1016/j.bbagen.2018.05.017. Epub 2018 May 30. PMID: 29857082

Suelves N, Miguez A, López-Benito S, Barriga GG, Giralt A, Alvarez-Periel E, Arévalo JC, Alberch J, Ginés S, Brito V. Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice. Mol Neurobiol. 2019 Feb;56(2):935-953. doi: 10.1007/s12035-018-1126-5. Epub 2018 May 27. PMID: 29804232

Saavedra A, García-Díaz Barriga G, Pérez-Navarro E, Alberch J. Huntington's disease: novel therapeutic perspectives hanging in the balance. Expert Opin Ther Targets. 2018 May;22(5):385-399. doi: 10.1080/14728222.2018.1465930. Epub 2018 Apr 26. Review. PMID: 29671352

Creus-Muncunill J, Rué L, Alcalá-Vida R, Badillos-Rodríguez R, Romaní-Aumedes J, Marco S, Alberch J, Perez-Otaño I, Malagelada C, Pérez-Navarro E. Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration. Mol Neurobiol. 2018 Oct;55(10):7728-7742. doi: 10.1007/s12035-018-0956-5. Epub 2018 Feb 19. PMID: 29460266

Alvarez-Periel E, Puigdellívol M, Brito V, Plattner F, Bibb JA, Alberch J, Ginés S. Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates. Mol Neurobiol. 2018 Aug;55(8):6250-6268. doi: 10.1007/s12035-017-0828-4. Epub 2017 Dec 29. PMID: 29288339

Cases S, Saavedra A, Tyebji S, Giralt A, Alberch J, Pérez-Navarro E. Age-related changes in STriatal-Enriched protein tyrosine Phosphatase levels: Regulation by BDNF. Mol Cell Neurosci. 2018 Jan;86:41-49. doi: 10.1016/j.mcn.2017.11.003. Epub 2017 Nov 6. PMID: 29122705

Giralt A, Gómez-Climent MÁ, Alcalá R, Bretin S, Bertrand D, María Delgado-García J, Pérez-Navarro E, Alberch J, Gruart A. The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice. Neuropharmacology. 2017 Sep 1; 123:395-409. doi: 10.1016/ j.neuropharm. 2017.06.009. Epub 2017 Jun 8. PMID: 28603025

Giralt A, Brito V, Chevy Q, Simonnet C, Otsu Y, Cifuentes-Díaz C, de Pins B, Coura R, Alberch J, Ginés S, Poncer JC, Girault JA. Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington's disease model. Nat Commun. 2017 May 30;8:15592. doi: 10.1038/ncomms15592. PMID: 28555636

García-Díaz Barriga G, Giralt A, Anglada-Huguet M, Gaja-Capdevila N, Orlandi JG, Soriano J, Canals JM, Alberch J. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway. Hum Mol Genet. 2017 Aug 15;26(16): 3144-3160. doi: 10.1093/ hmg/ ddx198. PMID: 28541476

HD iPSC Consortium. Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci. 2017 May;  20(5): 648-660. doi: 10.1038/ nn.4532. Epub 2017 Mar 20. PMID: 28319609

Martín-Ibáñez R, Pardo M, Giralt A, Miguez A, Guardia I, Marion-Poll L, Herranz C, Esgleas M, Garcia-Díaz Barriga G, Edel MJ, Vicario-Abejón C, Alberch J, Girault JA, Chan S, Kastner P, Canals JM. Helios expression coordinates the development of a subset of striatopallidal medium spiny neurons. Development. 2017 Apr 15; 144(8): 1566-1577. doi: 10.1242/ dev. 138248. Epub 2017 Mar 13. PMID: 28289129

Saavedra A, Fernández-García S, Cases S, Puigdellívol M, Alcalá-Vida R, Martín-Flores N, Alberch J, Ginés S, Malagelada C, Pérez-Navarro E. Chelerythrine promotes Ca(2+)-dependent calpain activation in neuronal cells in a PKC-independent manner. Biochim Biophys Acta Gen Subj. 2017 Apr; 1861(4): 922-935. doi: 10.1016/ j.bbagen. 2017.01.021. Epub 2017 Jan 24. PMID: 28130160

Canal M, Martín-Flores N, Pérez-Sisqués L, Romaní-Aumedes J, Altas B, Man HY,  Kawabe H, Alberch J, Malagelada C. Loss of NEDD4 contributes to RTP801 elevation  and neuron toxicity: implications for Parkinson's disease. Oncotarget. 2016 Sep 13; 7(37): 58813-58831. doi: 10.18632/ oncotarget. 11020. PMID: 27494837

Anglada-Huguet M, Giralt A, Rué L, Alberch J, Xifró X. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease. Biochim Biophys Acta. 2016 Jul; 1862(7): 1255-66. doi: 10.1016/ j.bbadis. 2016.04.002. Epub 2016 Apr 6. PMID: 27063456

Pont L, Benavente F, Jaumot J, Tauler R, Alberch J, Ginés S, Barbosa J, Sanz-Nebot V. Metabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools. Electrophoresis. 2016 Mar; 37(5-6): 795-808. doi: 10.1002/ elps. 201500378. Epub 2016 Feb 8.. PMID: 26685060

Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Vilarrasa-Blasi R, Sánchez-Pla A, Mosquera JL, Soriano J, López-Barneo J, Canals JM, Alberch J, Raya Á, Vila M, Consiglio A, Martín-Subero  JI, Ezquerra M, Tolosa E. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients. EMBO Mol Med. 2015 Dec; 7(12): 1529-46. doi: 10. 15252/ emmm. 201505439. PMID: 26516212

Puigdellívol M, Cherubini M, Brito V, Giralt A, Suelves N, Ballesteros J, Zamora-Moratalla A, Martín ED, Eipper BA, Alberch J, Ginés S. A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease. Hum Mol Genet. 2015 Dec 20; 24(25): 7265-85. doi: 10. 1093/ hmg/ ddv426. Epub 2015 Oct 12. PMID: 26464483

Straccia M, Garcia-Diaz Barriga G, Sanders P, Bombau G, Carrere J, Mairal PB, Vinh NN, Yung S, Kelly CM, Svendsen CN, Kemp PJ, Arjomand J, Schoenfeld RC, Alberch J, Allen ND, Rosser AE, Canals JM. Quantitative high-throughput gene expression profiling of human striatal development to screen stem cell-derived medium spiny neurons. Mol Ther Methods Clin Dev. 2015 Sep 16; 2:15030. doi: 10.1038/ mtm. 2015.30. eCollection 2015. PMID: 26417608

Anglada-Huguet M, Vidal-Sancho L, Giralt A, García-Díaz Barriga G, Xifró X, Alberch J. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity. Neurobiol Dis. 2016 Nov; 95: 22-34. doi: 10.1016/ j.nbd. 2015.09.001. Epub 2015 Sep 11. PMID: 26369879

Azkona G, Saavedra A, Aira Z, Aluja D, Xifró X, Baguley T, Alberch J, Ellman  JA, Lombroso PJ, Azkue JJ, Pérez-Navarro E. Striatal-enriched protein tyrosine phosphatase modulates nociception: evidence from genetic deletion and pharmacological inhibition. Pain. 2016 Feb;157(2):377-86. PMID: 26270590

Saavedra A, Puigdellívol M, Tyebji S, Kurup P, Xu J, Ginés S, Alberch J, Lombroso PJ, Pérez-Navarro E. BDNF Induces Striatal-Enriched Protein Tyrosine Phosphatase 61 Degradation Through the Proteasome. Mol Neurobiol. 2016 Aug; 53(6): 4261-4273. doi: 10.1007/ s12035- 015-9335-7. Epub 2015 Jul 30. PMID: 26223799

Puigdellívol-Sánchez A, Giralt A, Casanovas A, Alberch J, Prats-Galino A. Cryostat Slice Irregularities May Introduce Bias in Tissue Thickness Estimation: Relevance for Cell Counting Methods. Microsc Microanal. 2015 Aug; 21(4): 893-901. doi: 10.1017/ S143192761501380X. Epub 2015 Jul 15. PMID: 26173483

Cherubini M, Puigdellívol M, Alberch J, Ginés S. Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington's disease. Biochim Biophys Acta. 2015 Oct; 1852(10 Pt A): 2145-60. doi: 10.1016/ j.bbadis. 2015.06.025. Epub 2015 Jul 2. PMID: 26143143

Fernández-Nogales M, Hernández F, Miguez A, Alberch J, Ginés S, Pérez-Navarro E, Lucas JJ. Decreased glycogen synthase kinase-3 levels and activity contribute  to Huntington's disease. Hum Mol Genet. 2015 Sep 1; 24(17): 5040-52. doi: 10.1093/ hmg/ ddv224. Epub 2015 Jun 16. PMID: 26082469

Miguez A, García-Díaz Barriga G, Brito V, Straccia M, Giralt A, Ginés S, Canals JM, Alberch J. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation  and astrocyte-mediated inflammation. Hum Mol Genet. 2015 Sep 1; 24(17): 4958-70. doi: 10.1093/ hmg/ ddv218. Epub 2015 Jun 10. PMID: 26063761

Martín-Flores N, Romaní-Aumedes J, Rué L, Canal M, Sanders P, Straccia M, Allen ND, Alberch J, Canals JM, Pérez-Navarro E, Malagelada C. RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death. Mol Neurobiol. 2016 Jul; 53(5): 2857-2868. doi: 10.1007/ s12035-015- 9166-6. Epub 2015 Apr 16. PMID: 25876513

Xifró X, Vidal-Sancho L, Boadas-Vaello P, Turrado C, Alberch J, Puig T, Verdú E. Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in mice. PLoS One. 2015 Apr 9; 10(4): e0123122. doi: 10.1371/ journal. pone. 0123122. eCollection 2015. PMID: 25855977

Tyebji S, Saavedra A, Canas PM, Pliassova A, Delgado-García JM, Alberch J, Cunha RA, Gruart A, Pérez-Navarro E. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease. Neurobiol Dis. 2015 Feb; 74: 41-57. doi: 10.1016/ j.nbd. 2014.11.004. Epub 2014 Nov 11. PMID: 25449908

Brito V, Giralt A, Enriquez-Barreto L, Puigdellívol M, Suelves N, Zamora-Moratalla A, Ballesteros JJ, Martín ED, Dominguez-Iturza N, Morales M, Alberch J, Ginés S. Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction. J Clin Invest. 2014 Oct; 124(10): 4411-28. doi: 10.1172/ JCI74809. Epub 2014 Sep 2. PMID: 25180603

Romaní-Aumedes J, Canal M, Martín-Flores N, Sun X, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch  J, Luebbert H, Tolosa E, Levy OA, Greene LA, Malagelada C. Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death Dis. 2014 Aug 7; 5: e1364. doi: 10.1038/ cddis. 2014. 333. PMID: 25101677

Moreno B, Lopez I, Fernández-Díez B, Gottlieb M, Matute C, Sánchez-Gómez MV,  Domercq M, Giralt A, Alberch J, Collon KW, Zhang H, Parent JM, Teixido M, Giralt  E, Ceña V, Posadas I, Martínez-Pinilla E, Villoslada P, Franco R. Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine. PLoS One. 2014 Mar 5; 9(3): e90671. doi: 10.1371/ journal. pone. 0090671. eCollection 2014. PMID: 24599318

Anglada-Huguet M, Xifró X, Giralt A, Zamora-Moratalla A, Martín ED, Alberch J. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease. Mol Neurobiol. 2014 Apr; 49(2): 784-95. doi: 10.1007/ s12035-013-8556-x. Epub 2013 Nov 7. PMID: 24198227

Saavedra A, Giralt A, Arumí H, Alberch J, Pérez-Navarro E. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. PLoS One. 2013 Sep 5; 8(9): e73664. doi: 10.1371/ journal. pone. 0073664. eCollection 2013. PMID: 24040016

Rué L, Alcalá-Vida R, López-Soop G, Creus-Muncunill J, Alberch J, Pérez-Navarro E. Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease. Neuromolecular Med. 2014 Mar; 16(1): 25-37. doi: 10.1007/ s12017- 013- 8248-8. Epub 2013 Jul 30. PMID: 23896721

Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, Alberch J, Wesseling JF, Pérez-Otaño I. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nat Med. 2013 Aug; 19(8): 1030-8. doi: 10.1038/ nm. 3246. Epub 2013 Jul 14. PMID: 23852340

30: Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux  T, Déglon N, Beal MF, Brouillet E. A role of mitochondrial complex II defects in  genetic models of Huntington's disease expressing N-terminal fragments of mutant  huntingtin. Hum Mol Genet. 013 Oct 1; 22(19): 3869-82. doi: 10.1093/ hmg/ ddt242. Epub 2013 May 29. PMID: 23720495

Giralt A, Sanchis D, Cherubini M, Ginés S, Cañas X, Comella JX, Alberch J. Neurobehavioral characterization of Endonuclease G knockout mice reveals a new putative molecular player in the regulation of anxiety. Exp Neurol. 2013 Sep; 247: 122-9. doi: 10.1016/ j.expneurol. 2013.03. 028. Epub 2013 Apr 18.. PMID: 23603365

Brito V, Puigdellívol M, Giralt A, del Toro D, Alberch J, Ginés S. Imbalance  of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis. 2013 Apr 18; 4: e595. doi: 10.1038/ cddis. 2013.116. PMID: 23598407

Giralt A, Saavedra A, Carretón O, Arumí H, Tyebji S, Alberch J, Pérez-Navarro E. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model. Hippocampus. 2013 Aug; 23(8): 684-95. doi: 10. 1002/ hipo. 22128. Epub 2013 Apr 29. PMID: 23576401

Barroso E, del Valle J, Porquet D, Vieira Santos AM, Salvadó L, Rodríguez-Rodríguez R, Gutiérrez P, Anglada-Huguet M, Alberch J, Camins A, Palomer X, Pallàs M, Michalik L, Wahli W, Vázquez-Carrera M. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochim Biophys Acta. 2013 Aug; 1832(8): 1241-8. doi: 10.1016/ j.bbadis. 2013.03.006. Epub 2013 Mar 16. PMID: 23507144

Rué L, López-Soop G, Gelpi E, Martínez-Vicente M, Alberch J, Pérez-Navarro E. Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease. Neurobiol Dis. 2013 Apr; 52: 219-28. doi: 10. 1016/ j.nbd. 2012.12. 008. Epub 2013 Jan 4. PMID: 23295856

Canela L, Selga E, García-Martínez JM, Amaral OB, Fernández-Dueñas V, Alberch J, Canela EI, Franco R, Noé V, Lluís C, Ciudad CJ, Ciruela F. Transcriptional profiling of striatal neurons in response to single or concurrent activation of dopamine D2, adenosine A(2A) and metabotropic glutamate type 5 receptors: focus on beta-synuclein expression. Gene. 2012 Oct 25; 508(2): 199-205. doi: 10. 1016/ j.gene. 2012.07. 074. Epub 2012 Aug 7. PMID: 22892378

Carretón O, Giralt A, Torres-Peraza JF, Brito V, Lucas JJ, Ginés S, Canals JM, Alberch J. Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. Exp Neurol. 2012 Oct; 237(2): 335-45. doi: 10.1016/ j.expneurol. 2012.06. 033. Epub 2012 Jul 6. PMID: 22776425

Ruiz C, Casarejos MJ, Rubio I, Gines S, Puigdellivol M, Alberch J, Mena MA, de Yebenes JG. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Res. 2012 Jun 12; 1459: 100-12. doi: 10.1016/ j.brainres. 2012. 04.021. Epub 2012 Apr 21. PMID: 22560595

Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med. 2012 May; 4(5): 380-95. doi: 10.1002/ emmm. 201200215. Epub 2012 Mar 8. PMID: 22407749

Giralt A, Saavedra A, Alberch J, Pérez-Navarro E. Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms. J Huntingtons Dis. 2012; 1(2): 155-73. doi: 10.3233/ JHD- 120023. PMID: 25063329

Martín-Ibáñez R, Crespo E, Esgleas M, Urban N, Wang B, Waclaw R, Georgopoulos K, Martínez S, Campbell K, Vicario-Abejón C, Alberch J, Chan S, Kastner P, Rubenstein JL, Canals JM. Helios transcription factor expression depends on Gsx2  and Dlx1&2 function in developing striatal matrix neurons. Stem Cells Dev. 2012 Aug 10; 21(12): 2239-51. doi: 10.1089/ scd. 2011. 0607. Epub 2012 Jan 26. PMID: 22142223

Giralt A, Puigdellívol M, Carretón O, Paoletti P, Valero J, Parra-Damas A, Saura CA, Alberch J, Ginés S. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet. 2012 Mar 15; 21(6): 1203-16. doi: 10. 1093/ hmg/ ddr552. Epub 2011 Nov 24. PMID: 22116937

Xifró X, Anglada-Huguet M, Rué L, Saavedra A, Pérez-Navarro E, Alberch J. Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant  huntingtin toxicity. Mol Neurodegener. 2011 Oct 31; 6: 74. doi: 10. 1186/ 1750- 1326-6-74. PMID: 22041125

Giralt A, Carretón O, Lao-Peregrin C, Martín ED, Alberch J. Conditional BDNF release under pathological conditions improves Huntington's disease pathology by  delaying neuronal dysfunction. Mol Neurodegener. 2011 Oct 10; 6(1): 71. doi: 10.1186/ 1750- 1326-6-71. PMID: 21985529

Saavedra A, Giralt A, Rué L, Xifró X, Xu J, Ortega Z, Lucas JJ, Lombroso PJ,  Alberch J, Pérez-Navarro E. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J Neurosci. 2011 Jun 1; 31 (22): 8150-62. doi: 10. 1523/ JNEUROSCI. 3446- 10.2011. PMID: 21632937

Giralt A, Saavedra A, Carretón O, Xifró X, Alberch J, Pérez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum Mol Genet. 2011 Nov 1; 20(21): 4232-47. doi: 10. 1093/ hmg/ ddr351. Epub 2011 Aug 11. Epub 2011 Aug 11. PMID: 21835884

Sánchez-Gómez MV, Alberdi E, Pérez-Navarro E, Alberch J, Matute C. Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors. J Neurosci.

  • Offers from the University of Barcelona:

Work UB

  • Offers from the Research Group:

At the moment, there are no job offers from this Research Group

Share: